Last updated on August 2020

Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

Brief description of study

This trial will be conducted to demonstrate the efficacy and safety of vadadustat compared to darbepoetin alfa for the maintenance treatment of anemia in hemodialysis participants after conversion from current erythropoiesis-stimulating agent (ESA) therapy.

Detailed Study Description

This study consists of three periods:

  1. Screening Period
  2. Conversion and Maintenance Treatment Period
  3. Safety Follow-up Period

Individual participants will participate in total trial duration of approximately 64 weeks.

Clinical Study Identifier: NCT04313153

Find a site near you

Start Over

Research Site

Bethlehem, PA United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.